BOEHRINGER-INGELHEIM
9.5.2023 14:36:33 CEST | Business Wire | Press release
Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas. The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte. Ltd. (Enleofen), with a goal to improve patient outcomes.
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues. It can be triggered by different factors (such as infections, inflammation, autoimmune disorders, degenerative diseases, tumors, and injury), can cause organ dysfunction/failure, and affect the quality of life and survival of patients. Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis. Current treatments have led to progress in some areas, however fibrotic diseases remain to be a leading cause of morbidity/mortality and account for more than one third of deaths worldwide.
IL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases. Boehringer Ingelheim joined forces with Enleofen, a leader in IL-11 biology, in 2020.
“The initiation of this trial is an important milestone for Boehringer Ingelheim and brings us closer to achieving our aim of transforming lives of people living with fibrotic diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The effects shown for anti-IL-11 preclinically are impressive and could, if confirmed in the clinic, herald a dramatic advance in the treatment of fibrotic diseases.”
“Enleofen is very excited to see the IL-11 inhibitor partnership with Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D, moving forward into the clinic to address unmet patient needs,” said Prof Stuart Cook, co-founder of Enleofen and Tanoto Foundation Professor of Cardiovascular Medicine at the SingHealth Duke-NUS Academic Medical Centre and the Cardiovascular & Metabolic Disorders Programme at Duke-NUS Medical School, Singapore.
The IL-11 program complements Boehringer Ingelheim’s clinical fibrotic disease pipeline portfolio which includes BI 1015550, a phosphodiesterase 4B (PDE4B) inhibitor, under investigation in two Phase III randomized, double-blind, placebo-controlled trials—FIBRONEER™-IPF (NCT05321069) and FIBRONEER™-ILD (NCT05321082)—to investigate the efficacy, safety and tolerability of BI 1015550 over at least 52 weeks in patients with IPF and in patients with other progressive fibrosing ILDs and several other clinical stage programs.
###
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com
About Enleofen
Enleofen is a Singapore-based biotech company developing first-in-class antibody therapeutics for the treatment of fibro-inflammatory human diseases. The initial discovery science and drug target validation was carried out by founders Stuart Cook and Sebastian Schäfer at the National Heart Centre Singapore at SingHealth and Duke-NUS Medical School and was subsequently licensed to Enleofen. Since 2017, the company has invested extensively in target validation, drug development, and preclinical studies, with the support of experienced international life sciences executives and investors, including founding directors Jeffrey Lu and Andrew Khoo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005762/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku Enters Strategic Alliance with Onto Innovation through 27 % Equity Investment21.4.2026 01:14:00 CEST | Press release
Expanding Semiconductor Opportunities through X-ray, Optical, and AI Integration Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), a global leader in X-ray analytical technologies, today announced that it has entered into a strategic capital and business alliance with Onto Innovation Inc. (headquarters: Massachusetts, USA; CEO: Michael P. Plisinski; “Onto Innovation”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420467739/en/ Double Logo “As semiconductor devices become more complex, particularly with the increasing importance of three-dimensional structures, Rigaku has been seeking to enhance its analytical capabilities by incorporating advanced model-based and AI-driven algorithms in optical metrology,” said Jun Kawakami, President and CEO, Rigaku Holdings Corporation. “Onto Innovation not only brings strong expertise in optical technologies and software, but also
Grid Dynamics Scales Hyper-Personalization for Galeries Lafayette; Drives 7% Revenue Increase via AI-Powered Search and Merchandising20.4.2026 22:05:00 CEST | Press release
Key Takeaways: Galeries Lafayette achieved a 7% total revenue increase and an 8% rise in average basket value by replatforming its legacy search and recommendation stack with Google Vertex AI Search for Commerce and Grid Dynamics' proprietary Merchandising Experience Platform (MXP). The solution successfully modernized a complex catalog of over 600,000 products—including 350,000 from third-party marketplaces—contributing to a 20% year-over-year increase in online sales. This successful program showcases Grid Dynamics’ expertise in bridging the gap between advanced AI models and measurable retail profitability for global enterprises. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, today announced the successful deployment of a hyper-personalized digital shopping experience for Galeries Lafayette, the iconic French department store. By integrating Google Vertex AI Search for Commerce with the proprietary Grid Dynami
Lattice Collaborates with TI to Accelerate Edge AI for Robotics and Industrial Applications20.4.2026 22:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that the company is collaborating with Texas Instruments (TI) to simplify sensor integration and to scale real-time edge AI systems. The combination of TI’s sensing technologies and the Lattice Holoscan Sensor Bridge solution, based on Lattice low power FPGA technology, will provide developers with a flexible hardware foundation for synchronized, low latency sensor data pipelines in advanced robotics and industrial applications. The collaboration demonstrates a real-time AI sensor fusion architecture that integrates TI mmWave radar and camera sensors using NVIDIA Holoscan Sensor Bridge running on Lattice’s low power FPGA. The FPGA acts as a companion chip delivering synchronized sensor data directly into GPU-accessible memory to enable low latency and robust perception for robotics and industrial edge AI applications. “As edge AI systems scale, developers need flexible platforms that simplify senso
Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st
Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys20.4.2026 16:00:00 CEST | Press release
Industry’s most widely adopted PETG material meets industry-leading cleanliness, compliance, and RNase/DNase-free validation—now available across the full bioprocessing workflow. SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with SaniSure’s proprietary process and advanced automation. This launch expands SaniSure’s established PharmaTainer® platform—extending its proven cleanliness, robustness, and performance attributes to include industry-standard PETG alongside its existing PET and PC offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420641769/en/ PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bioprocessing applications. Available in volumes from 10 mL stability vials to 10 L carboys — in sterile (gamma-irradiated) an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom